Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F24%3A10158773" target="_blank" >RIV/00098892:_____/24:10158773 - isvavai.cz</a>

Result on the web

<a href="https://onlinelibrary.wiley.com/doi/10.1002/hem3.70004" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/hem3.70004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hem3.70004" target="_blank" >10.1002/hem3.70004</a>

Result language

angličtina

Original language name

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Original language description

The introduction of novel small molecule inhibitors has transformed the management of chronic lymphocytic leukemia (CLL), demonstrating superiority over traditional chemoimmunotherapy (CIT) in various settings. This retrospective study by the European Research Initiative on CLL (ERIC) analyzed real-world treatment patterns and outcomes among 7,382 patients diagnosed with CLL or small lymphocytic lymphoma (SLL) from 2000 to 2016 across 76 centers in 25 countries. The median age at diagnosis was 64 years, with most patients (93.2%) receiving at least one line of chemotherapy or CIT. The most prevalent first-line regimen was FCR (35.3%), particularly among younger patients. While BTK inhibitors (BTKis) were used in only 2% of patients as frontline treatment, they were the most common therapy for relapsed/refractory (R/R) cases. Notably, the study found that chemotherapy and CIT usage decreased after 2014, with significant variations in treatment choices for R/R patients. Discontinuation due to toxicity was a concern, especially among patients treated with PI3K inhibitors, while venetoclax showed a lower discontinuation rate. The study highlighted the delayed adoption of novel agents, even after their proven efficacy, raising questions about treatment accessibility and physician decision-making. Despite limitations, the findings underscore the need for improved integration of novel therapies into clinical practice and a better understanding of the barriers to their use.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

HemaSphere

ISSN

—

e-ISSN

2572-9241

Volume of the periodical

8

Issue of the periodical within the volume

9

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

"e70004"

UT code for WoS article

001314048700001

EID of the result in the Scopus database

2-s2.0-85204215391